The severe inhibition of tumor growth and peritoneal spread by BTYNB demonstrated in experimental tumor models provides strong, pre-clinical evidence that the therapeutic inhibition of IGF2BP1 is feasible. The gene discussed is IGF2BP1; the disease is neoplasm.